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Schiller and Phelps (2011) have provided 
a thoughtful and comprehensive review in 
the May issue of Frontiers in Behavioral 
Neurosciences entitled, “Does reconsoli-
dation occur in humans?” This scholarly 
paper captures many of the challenges in 
translating the animal research on recon-
solidation to humans. We agree with their 
main argument that there is little published 
evidence in humans that meets one impor-
tant reconsolidation criterion, namely, that 
the memory-weakening treatment should 
be administered after the memory reacti-
vation, so as not to influence the preced-
ing memory retrieval process. However, it 
is unclear whether pre-reactivation pro-
pranolol significantly hampers memory 
retrieval. On the basis of this uncertainty, 
Schiller and Phelps go on to suggest that the 
memory impairing effects of pre-reactiva-
tion propranolol (e.g., Kindt et al., 2009; 
Brunet et al., 2011) must be explained by 
some process other than reconsolidation. 
Such a conclusion appears illogical, because 
if propranolol does not impair retrieval 
sufficiently to preclude reconsolidation, 
then blockade of memory reconsolidation 
remains a viable explanation for pre-reac-
tivation propranolol’s memory-weakening 
action. Indeed, the ultimate evidence for 
successful memory retrieval is measured 
during reactivation (e.g., freezing behavior 
in rodent fear conditioning, GSR in human 
fear conditioning, etc.). Therefore, any 
impairment of retrieval should be detected. 
Moreover, as shown recently by Debiec 
et al. (2011) immediate post-retrieval beta-
adrenergic receptor stimulation enhances 
reconsolidation of fear conditioning in the 
amygdala. In this scenario, administration 
of propranolol following memory retrieval 
(which results in arousal and noradrenergic 
stimulation) may be too late to be effective.
So, a parsimonious explanation is that 
pre-reactivation propranolol did block 
reconsolidation to some extent in the 
above-mentioned studies.
Pre-reactivation propranolol studies 
(and other studies with a similar design) 
ought to be pursued vigorously because, 
irrespective of how the memory impairing 
effect is obtained, they offer the prospect of a 
novel approach to treating mental disorders 
that have at their core an emotional, usually 
traumatic, memory. Although Schiller and 
Phelps acknowledge some of the challenges 
of blocking reconsolidation using pharma-
cological means in humans, it is important 
to note the reasons for this difficulty. In 
animals, reconsolidation (i.e., protein syn-
thesis) is believed to begin 3–10 min after 
memory reactivation (Monfils et al., 2009). 
Most of it appears to take place within the 
first 2 h (Przybyslawski et al., 1999) and 
to be over by the sixth hour (Duvarci 
and Nader, 2004). Considering that oral 
propranolol takes about 90 min to reach 
its peak bioavailability in human blood 
(Marino, 1987); and considering that only 
a fraction of this drug will eventually cross 
the blood–brain barrier to be available to 
exert the necessary effect, protocols that use 
post-reactivation propranolol are vulner-
able to yielding negative results because 
not enough protein synthesis will have 
been blocked by the time the drug reaches 
its full effect in the human brain. Since 
conducting our proof-of-concept study 
in posttraumatic stress disorder (PTSD; 
Brunet et al., 2008), which used post-reac-
tivation propranolol, we have opted to use 
pre-reactivation propranolol in an attempt 
to develop what we hope will be a more 
potent therapeutic protocol (see Brunet 
et al., 2011). It is unfortunate that this type 
of protocol does not meet an important sci-
entific criterion for studies that use it to be 
labeled as genuine “reconsolidation” stud-
ies, but this is the price to pay for conduct-
ing sound translational research in patients. 
Schiller et al. (2010) are to be commended 
for their efforts to devise a human protocol 
that circumvents the problems associated 
with pharmacological blockade of recon-
solidation by incorporating new material 
into a destabilized old memory, rather 
than simply blocking its reconsolidation. 
However, they have yet to show that such 
an approach is sufficiently potent to help 
patients overcome their psychological 
symptoms   stemming from a traumatic 
emotional memory.
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